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Abstract8
Pain relief, or a decrease in self-reported pain intensity, is frequently the primary outcome of pain9
clinical trials. Investigators commonly report pain relief in one of two ways: using raw units (additive)10
or using percentage units (multiplicative). However, additive and multiplicative scales have different11
assumptions and are incompatible with one-another. In this work, we describe the assumptions and12
corollaries of additive and multiplicative models of pain relief to illuminate the issue from statistical13
and clinical perspectives. First, we explain the math underlying each model and illustrate these points14
using simulations, for which readers are assumed to have an understanding of linear regression. Next, we15
connect this math to clinical interpretations, stressing the importance of statistical models that accurately16
represent the underlying data; for example, how using percent pain relief can mislead clinicians if the17
data are actually additive. These theoretical discussions are supported by empirical data from four18
longitudinal studies of patients with subacute and chronic pain. Finally, we discuss self-reported pain19
intensity as a measurement construct, including its philosophical limitations and how clinical pain differs20
from acute pain measured during psychophysics experiments. This work has broad implications for21
clinical pain research, ranging from statistical modeling of trial data to the use of minimal clinically22
important differences and patient-clinician communication.23
1 Introduction24
Pain is highly prevalent, burdensome, and a common reason for doctor visits [Gaskin and Richard, 2012,25
St Sauver et al., 2013, Vos et al., 2020, Mntyselk et al., 2001]. In an attempt to understand the severity26
of the patients’ pain, doctors and researchers ask patients about the intensity of the their pain, requiring27
patients to condense and transmute their subjective experience to a single number. Despite its abstract28
and reductionist nature, self-reports of pain intensity are moderately-to-strongly correlated with several29
patient-reported outcome variables, including quality of life, disability, and more [Yazdi-Ravandi et al., 2013,30
Nasution et al., 2018]. Moreover, self-reports of pain intensity are remarkably easy and inexpensive to collect.31
These pragmatic and measurement properties make a reduction in self-reported pain, which we define as32
pain relief, the gold standard for assessing pain improvement.33
Clinical studies of pain commonly quantify pain relief as the primary outcome. However, how pain34
relief is quantified and reported roughly falls into one of two categories: absolute reductions in pain and35
relative (or percent) reductions in pain. For example, studies that report absolute reduction may state36
that a drug decreased pain by 2/10 numerical rating scale (NRS) units or 23/100 visual analog scale (VAS)37
units. Alternatively, studies that report relative reductions may state that pain decreased by 13 percentage38
units more in the drug group relative to the placebo group. Although both approaches to reporting pain39
reductions are common, they are conceptually incompatible (unless baseline pain is perfectly homogeneous;40
see Statistical Background). Their incompatibility begs the question as to whether one approach is more41
appropriate than the other.42
In this paper, we aim to illuminate the issue of absolute versus relative pain relief.1 We rely on statistical43
theory to provide researchers and statistically-minded clinicians with the background necessary to understand44
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Figure 1: Graphical illustration of the hierarchical model from which patients’ pain scores are sampled. The
broad yellow (light grey) distribution is the between-patient distribution (level 2), from which each patient’s
mean pain score is sampled. Each red (dark grey) distribution is a within-patient distribution (level 1), from
which single measurements are sampled.
these measurement models, for which readers are assumed to be familiar with linear regression. In addition,45
we empirically analyze four datasets to reinforce and make tangible our conceptual discussion.46
2 Statistical Background47
Whenever one uses data to make a calculation, they are building a model. Every model has assumptions,48
but still, models should accurately reflect the data they are intending to simplify and thus represent. With49
regards to modeling pain relief, when reporting absolute changes in pain, one is assuming the process is50
additive. Alternatively, when reporting percent changes in pain, one is assuming the process is multiplicative.51
These assumptions have corollaries that prima facie may be unclear. In this section, we aim to explain the52
processes that would generate each of these models and the theoretical implications of these measurement53
and modeling assumptions.54
2.1 Additive Model55
The additive model and its implications are best understood by defining a data-generating process. This56
involves creating a mathematical model that reflects how one thinks the data are created. Because longi-57
tudinal pain relief is of interest, there is commonly at least one pain rating at the beginning of the study58
(xi) and at least one or more follow-up ratings (yi) for each subject i. The additive model of pain relief59
uses the simple difference between these pain ratings to calculate absolute pain relief (δi = yi − xi), where60
negative δi’s indicate relief and positive δi’s indicate worsening of pain. Although straightforward, this is a61
gross oversimplification.62
In reality, the pain data are messy. For one, between-patient heterogeneity is appreciable—pain ratings at63
intake will often range from the minimum required for study entry (e.g., 4/10 NRS) to the scale’s maximum64
(e.g., 10/10 NRS). In addition, patients’ pain fluctuates from minute-to-minute, hour-to-hour, day-to-day,65
and so on. To complicate matters further, the process of converting a qualia to a number is undoubtedly66
fuzzy, meaning the pain ratings themselves will have noise associated with them. Thus, there are two sources67
of variance to consider: between patients and within patients. These sources of variance can be thought of68
hierarchically (Figure 1).69
Between-patient heterogeneity is a natural place to start. The entire sample of patients will have a mean70
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Figure 2: Properties of additive and multiplicative
data. We simulated data with additive (top) and mul-
tiplicative (top) assumptions. (A) Relationships be-
tween pre- and post-intervention pain scores when im-
provements are additive (top) and multiplicative (bot-
tom). Note the additive post-intervention scores are
relatively homoscedastic, while the variance of mul-
tiplicative post-intervention scores increases with in-
creasing pre-intervention scores. (B) Negative rela-
tionships between change scores and pre-intervention
scores. Grey areas in (B) represent regions where
points are not possible due to measurement con-
straints; that is, because a change score cannot be
> |100|.






This distribution of patient means is illustrated in yellow in Figure 1.73
The notion of within-patient heterogeneity implies there will be variance around each patient’s mean pain.74
When we ‘sample’ a patient’s pain rating, we do not observe αi; rather, we obtain a value αi ± σ. These75
within-patient distributions are illustrated in red in Figure 1. Together, the within- and between-patient76
models form a hierarchical model (Appendix A).77
Because the patient’s pre- and post-intervention pain ratings have variability associated with them, the78
observed difference scores are subject to regression toward the mean (RTM). RTM is a statistical phenomenon79
whereby higher initial scores are likely to be followed by lower measurements, and similarly, lower initial80
scores are likely to followed by higher measurements. For example, suppose someone’s diastolic blood pressure81
is normally around 70 mmHg. If a doctor measures that individual’s blood pressure and finds it to be 9082
mmHg, it is highly probable that the next time it is measured, it will be lower than 90 mmHg. Individuals83
whose measurements deviate more from their mean will thus appear to undergo greater changes. In the84
case of a pain study, those who start off with greater pain levels will regress toward the mean, in turn85
creating larger change scores. Importantly, this phenomenon is purely statistical and can be explained by86
the reliability of the measurement.87
Measurement reliability is commonly quantified using the intraclass correlation coefficient (ICC). The88




where τ2 is the between-patient variance and σ2 is the within-patient variance. Since σ2 defines the variance90
between individual measurements from a single patient, the ICC can be improved by using the mean of several91
measurements from a single patient rather than a single measurement. Doing so allows us to substitute σ292
with the variance of the sample mean, σ
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Figure 3: Simulations of additive and multiplicative changes reveal the effect of different intraclass correlation
coefficients on the slope between change scores and pre-intervention scores. Additive effects have slopes that
trend towards zero with increasing ICC’s, while multiplicative effects always have a negative slope no matter
their ICC.






Note, this quantity approaches 1 (perfect reliability) as n → ∞.95
Importantly, the above concepts generalize to post-intervention scores as well. If we assume τ2 and σ2 do96
not change, and instead, there is a simple shift in mean scores without ceiling and floor effects, then the ICC97
also defines the Pearson correlation between pre- and post-intervention scores. The Pearson correlation is98
useful because it gives us direct insight into RTM—the slope between the pre-intervention scores and change99
scores approaches zero as the correlation between pre- and post-intervention scores approaches 1 (Figure 3).100
This is depicted graphically in Figure 2b, which shows that those who have greater pre-intervention pain101
scores (x-axis) have smaller change scores (y-axis).102
All of these properties come together and should be considered when statistically modeling pain relief103
and the effect of an intervention.104
2.2 Multiplicative Model105
The multiplicative model is still mathematically simple but its implications are more complex. If pain relief106
is multiplicative, then it can be modeled as a relative reduction; i.e., φ = δixi . This would imply that each107
person’s post-intervention pain (yi) is a fraction of their starting pain (xi); i.e., yi = (φ + 1)xi. However,108
ratios and relative reductions have unfavorable statistical properties. Instead, it is preferable to work on109
the log scale [Keene, 1995, Senn, 2006, Senn and Julious, 2009]. In particular, recall log yixi = log yi − log xi,110
enabling us to linearize the multiplicative process. Similarly, from this, one may realize that it is natural to111
model multiplicative effects as being generated from log-normal distributions rather than normal distributions112
(Appendix B).113
The implications of the log-normal distribution and its multiplicative properties are shown and described114
in Figure 2 and Figure 3. Note that the multiplicative pain reductions follow different distribution than115
additive effects owing to their errors compounding rather than adding. This results in a ‘fanning’ (or116
heteroscedasticity) of post-intervention scores as a function of greater pre-intervention scores Figure 2a.117
This is a hallmark of multiplicative processes that can be evaluated empirically. In addition to this fanning,118
it is quickly apparent that even with zero measurement error (Figure 3), multiplicative effects can look like119
RTM since greater pre-intervention scores will result in greater decreases in pain (Figure 2b). However,120
as opposed to additive processes in which greater pre-intervention scores are attributable to RTM (i.e.,121
measurement error), this relationship is indeed ‘real’ for multiplicative processes.122
The multiplicative nature does not only apply to the relationship between pre- and post-intervention123




2.3 Statistical Models of Pain Relief125
Randomized controlled clinical trials aim to compare pain between two groups. To do so, investigators126
commonly compare the absolute or percent pain relief itself (e.g., a t-test on the change scores). However,127
such analyses are ill-conceived. Instead, especially for studies that record one or few follow-up measures (as128
opposed to time-series), it is recommended that the data-generating process be modeled using an analysis of129
covariance (ANCOVA) with pre-intervention scores as a covariate [Vickers and Altman, 2001, Senn, 2006].130
The reasons for this are manifold:131
1. The response variable in a statistical model should be the result of an experiment. Because patients132
enter studies with their baseline score, it is not the result of the experiment so it should not be treated133
as a dependent variable (e.g., like in a group×time analysis of variance).134
2. Accounting for RTM. Instead of a group×time analysis of variance, one could perform a simple t-test135
on the change scores. However, such an analysis ignores RTM, and, especially in the case of baseline136
imbalances, can produce biased estimates. ANCOVA can adjust for such effects.137
3. Improving statistical efficiency. ANCOVA has greater statistical efficiency, resulting in greater power138
and more precise intervals.139
4. Post-intervention scores are arguably more interesting than change scores. Patients must live with the140
pain following the intervention, not the change in pain. However, regressing post-intervention pain or141
change in pain produces the same group effect [Senn, 2006].142
These statistical and philosophical advantages are well-established in the biostatistics literature [Vickers and Altman, 2001,143
Vickers, 2001, Vickers, 2014, Frison and Pocock, 1992, Borm et al., 2007, Senn, 2006]. Note, the benefits144
of ANCOVA primarily apply to randomized studies, as ANCOVA may produce biased estimates in non-145
randomized studies depending on the allocation mechanism [Van Breukelen, 2006].146
For the additive case, the ANCOVA model takes the form147
yi = β0 + β1xi + β2gi + εi,
where εi ∼ N (0,σ2) and gi is dummy-coded for group (e.g., 0 = placebo and 1 = drug). β2 is the effect148
of interest: the average difference in post-intervention pain scores between groups after adjusting for pre-149
intervention scores. β1 will typically be < 1, indicative of RTM, and the intercept may be nonsensical unless150
xi is mean-centered. Of course, like any regression, one can add more covariates, especially those with151
prognostic value, which will further increase statistical efficiency.152
The ANCOVA can also be generalized to the multiplicative case. Since multiplicative effects can be153
linearized by taking the log-transform, we can write the model as154
yi = B0 · xβ1i ·B
gi
2 · Ei (1)
= exp {β0 + β1 log xi + β2gi + εi} (2)
=⇒ log yi = β0 + β1 log xi + β2gi + εi. (3)
This model reveals a few things. First, in (1), residuals will compound with increasing values of the predicted155
yi (i.e., ŷi). Indeed, this is consistent with what we observed in the simulations above, so this functional156
form can capture the compounding error. Second, in (3), both yi and xi are logged, so when β1 = 1,157
it is equivalent to modeling the percent change; however, when β1 ∕= 1, there is a scaling to account for158
nonlinearities and RTM. Finally, B2 is a multiplicative effect: when B2 = 1, both groups are expected to159
have the same post-intervention score for a given pre-intervention score; when B2 > 1, the experimental160
group is expected to have a greater post-intervention score for a given pre-intervention score; and so on.161
Since we are fitting β2 rather than B2, the fit coefficient will be on the log scale, so exponentiating the162
coefficient will make it more interpretable despite the log scale having nicer mathematical properties. Note,163

































Figure 4: Simulations of additive and multiplicative changes reveal differential residual behavior for raw
and log-transformed ANCOVA models. (Left) data generated with have an additive structure have ho-
moscedastic residuals when fit with a standard ANCOVA (top) but heteroscedastic residuals when fit with
a log-transformed ANCOVA (bottom). (Right) data generated with a multiplicative structure have ho-
moscedastic residuals when fit on their raw scale (top) but homoscedastic residuals when log-transformed
(bottom).
3 Empirical Data165
As a proof of principle, we assessed the properties of four separate datasets. Two of the datasets were166
collected in patients with subacute back pain and the other two consist of patients with chronic back pain.167
Ideally, data are analyzed using intention-to-treat. However, here, we included individuals for whom we had168
enough ratings to complete our analyses as the data are being used for illustrative purposes and we are not169
looking to draw inferences.170
3.1 Datasets171
3.1.1 Placebo I (Chronic back pain)172
Overview. The purpose of this study was to investigate factors associated with placebo analgesia in chronic173
pain patients [Vachon-Presseau et al., 2018]. This was the first trial designed to study chronic pain patients174
receiving placebo versus no treatment. The total duration of the study lasted ∼ 15 months. Protocol and175
informed consent forms were approved by Northwestern University IRB and the study was conducted at176
Northwestern University (Chicago, IL, USA).177
Participants. To meet inclusion criteria, individuals had to be 18 years or older with a history of lower178
back pain for at least 6 months. This pain should have been neuropathic (radiculopathy confirmed by179
physical examination was required), with no evidence of additional comorbid chronic pain, neurological, or180
psychiatric conditions. Individuals had to agree to stop any concomitant pain medications and had to be181
able to use a smartphone or computer to monitor pain twice a day. Additionally, the enrolled patients had182
to report a pain level of at least 5/10 during the screening interview, and their averaged pain level from the183
smartphone app needed to be higher than 4/10 during the baseline rating period before they were randomized184
into a treatment group. A total of 82 patients were randomized. Here, we include 18 participants from the185
no treatment group and 42 participants from the placebo group for whom we had complete rating data (cf.186




Pain data. Data were collected using a custom pain rating phone app through which patients could rate188
their pain (0–10 NRS). Patients were asked to enter their pain 2 times/day over the course of the entire189
study. For the purposes of demonstration, here we averaged pain ratings within a single day.190
3.1.2 Placebo II (Chronic back pain)191
Overview. The purpose of this study was to validate a prognostic model for classifying chronic pain patients192
based on their predicted improvement with placebo [Vachon-Presseau et al., 2021]. Protocol and informed193
consent forms were approved by Northwestern University IRB and the study was conducted at Northwestern194
University (Chicago, IL, USA).195
Participants. Individuals with chronic low back pain were recruited for this study. Patients must have196
had low back pain for at least 6 months, with or without symptoms of radiculopathy, a minimum VAS score197
of 5/10 at the screening visit and a minimum average pain of 4/10 over a two-week period prior to their first198
visit. A total of 94 patients were randomized to no treatment, placebo, or naproxen. Here, we include 12199
participants from the no treatment group, 33 participants from the placebo group, and 35 participants from200
the naproxen group for whom we had complete rating data (cf. Figure 1 in [Vachon-Presseau et al., 2021]).201
Pain data. Data were collected using a custom pain rating phone app through which patients could rate202
their pain (0–10 NRS), as in Placebo I. Patients were asked to enter their pain 2 times/day over the course203
of the entire study. For the purposes of demonstration, here we averaged pain ratings within a single day.204
3.1.3 Levodopa trial (Subacute back pain)205
Overview. The purpose of this trial was to investigate whether levodopa (l-DOPA) can block patients’206
transition from subacute to chronic back pain. This 24-week double-blind parallel randomized controlled207
trial was conducted at Northwestern University (Chicago, IL, USA). Protocol and informed consent form208
were approved by Northwestern University IRB as well as NIDCR/NIH. All enrolled participants provided209
written informed consent. The trial was registered on ClinicalTrials.gov, under registry NCT01951105 and210
is preprinted on medRχiv [Reckziegel et al., 2021].211
Participants. Individuals with a recent onset of lower back pain were recruited. Criteria for enrollment212
included history of lower back pain with duration between 4-20 weeks with signs and symptoms of radicu-213
lopathy and average reported pain intensity > 4 (on an NRS scale from 0 to 10) on the week before baseline214
assessments and the week preceding treatment start. Participants were randomized to one of three groups:215
no treatment (completed n=10), naproxen + placebo (n=28), naproxen + l-DOPA/c-DOPA (n=21). Here,216
we will use data from 47 patients who had complete rating data (naproxen + placebo = 27; naproxen +217
l-DOPA/c-DOPA = 20) (cf. Figure 1b, [Reckziegel et al., 2021]).218
Pain data. Data were collected using a custom pain rating phone app through which patients could rate219
their pain (0–10 NRS). Patients were asked to enter their pain 3 times/day over the course of the entire220
study (28 weeks). For the purposes of demonstration, here we averaged pain ratings within a single day.221
3.1.4 Prospective cohort (Subacute back pain)222
Overview. The purpose of this study was to identify predictive biomarkers to identify individuals who will223
vs. will not recover from subacute back pain [Baliki et al., 2012]. Protocol and informed consent forms224
were approved by Northwestern University IRB as well as NIDCR/NIH, and the study was conducted at225
Northwestern University (Chicago, IL, USA). All enrolled participants provided written informed consent.226
All participants were righthanded and were diagnosed by a clinician for back pain. An additional list of227
criteria was imposed including: pain intensity > 40/100 on the visual analog scale (VAS) and duration < 16228
weeks.229
Participants. Eighty individuals with a recent onset (within 16 weeks) of lower back pain and an average230
reported pain intensity > 40/100 (on the VAS) who completed at least three follow-up visits (i.e., 30 weeks231
following the initial visit).232
Pain data. Data were collected at 5 separate visits using the short form of the McGill Pain Questionnaire233
(MPQ). The computed sensory and affective scores from the MPQ for each visit are used as individual pain234





To evaluate whether each dataset was more compatible with an additive or multiplicative process, we con-237
ducted the same analyses from the Statistical Background section (Figures 2–4) on these data. In particular,238
we investigated properties of the raw and log-transformed data, in addition to the properties of ANCOVAs239
fit to the data. To do so, all data were converted to a 0–100 scale. Before log-transforming, we added 1 to240
the raw scores to avoid log(0) = NaN. In doing so, we demonstrate how the aforementioned principles apply241
to real data.242
All datasets have positive relationships between pre- and post-intervention scores(Figure 5, top row).243
Interestingly and in contrast to the other studies, the variance of the post-intervention scores in the levodopa244
trial appears to increase with greater pre-intervention scores, consistent with a multiplicative effect. Finally,245
with the exception of the prospective cohort study, there are negative relationships between changes in pain246
and pre-intervention scores. These negative relationships may be explained by multiplicative effects or RTM.247
Further examination is needed to ascertain the nature of these data.248

















Figure 5: Relationships between pre-intervention scores and change scores (top) and pre-intervention scores
(bottom). (Top) Relationship between pre-intervention scores and change scores. Note that most of the
studies have a negative relationship. This could be explained by regression toward the mean or multiplicative
effects, in addition to ceiling/floor effects. (Bottom) Relationship between pre-intervention and post-
intervention pain scores across all studies. Each study shows a positive relationship between pre- and
post-intervention scores; however, the Levodopa study appears to have greater variance in post-intervention
scores with greater pre-intervention scores.
Including more points in the calculation of pre-intervention and post-intervention scores increases the249
ICC, thereby increasing the reliability and decreasing the effect of RTM (Figure 3). Since three of the four250
datasets contained ecological momentary assessments of pain, we were able to sample and average more251
than one point from the beginning and end of each study. We averaged an increasing number of a pre- and252
post-intervention points and recalculated the slope between change score and pre-intervention score (i.e.,253
plot from Figure 5, top). If the slopes strongly trend towards zero by increasing the number of points, this254
indicates that the data have additive properties. Slopes that stay negative regardless of increasing reliability255
(number of points) indicate that the data may be multiplicative. For the studies included in this analysis256
(Placebo I, Placebo II, Levodopa Trial), Placebo I and Placebo II’s slopes have slight upward trends: as the257
number of points in the calculation of pre-intervention and post-intervention scores increases, the negative258





again hints at the notion that the levodopa trial’s data may be multiplicative, while Placebo I and Placebo260
II may be additive.261
Placebo 1 Placebo 2 Levodopa










Figure 6: Increasing the number of points used for each patient’s pre- and post-intervention scores increases
the slope between change scores and pre-intervention scores. Each patient’s pre- and post-intervention scores
were calculated using the mean of x points. By averaging over more points, we should increase the intraclass
correlation coefficient. Negative slopes between change scores and pre-intervention scores are indicative of
one of two things: (1) regression toward the mean or (2) multiplicative effects. In the datasets that show
evidence of being additive, we see marked increases in slopes, indicating that we are decreasing regression
toward the mean by including more points. However, because the Levodopa Trial displays multiplicative
properties, it is only minimally affected by adding more points.
Perhaps the most direct assessment of additive versus multiplicative properties is to model the data and262
assess the model fits. When assessing and utilizing a model, one should ensure that the model’s assumptions263
are met and that the model captures salient features of the data. Because multiplicative data-generating264
processes lead to compounding residuals, we can observe these effects when fitting ANCOVAs. In Figure 7,265
we focus specifically on the variance observed in Figure 5, illustrating the relationship between fitted values266
(using the ANCOVA models from Figure 5) and the absolute value of the residuals. As shown in Figure 2,267
multiplicative relationships possess higher variance as pre-intervention scores increase, compared to additive268
relationships which are homoscedastic. For this reason, we should observe a null correlation between fitted269
values and absolute residual error for data that have exhibited additive properties (Placebo I, Placebo II,270
Prospective Cohort) thus far, and observe a positive correlation between fitted values and absolute residual271
error for data that have exhibited multiplicative properties (Levodopa Trial). As predicted, the Placebo I,272
Placebo II, and Prospective Cohort data all display this additive quality, as their residual error does not273
increase as fitted values increase. In contrast, the Levodopa Trial data display multiplicative properties, as274


































Figure 7: Absolute values of residuals from additive ANCOVA models. We fit an ANCOVA to each dataset
using pre-intervention score and group membership as covariates. From these models, we plotted the absolute
values of the residuals as a function of the fitted value. Additive models should be homoscedastic, meaning
the magnitudes of the residuals do not change as a function of the response variable. However, multiplicative
models have compounding error, such that if you fit them using an additive model, greater predicted values
will be associated with larger magnitudes of residual error. Placebo I, Placebo II, and the Prospective Cohort
study all exhibit features of additive data. However, the Levodopa Trial exhibits multiplicative properties,
as evidenced by the increasing error residual magnitude with increasing fitted values.
From these plots, it is clear that the Placebo I, Placebo II, Prospective Cohort demonstrate additive277
properties while the Levodopa Trial demonstrates multiplicative properties. An understanding of these278
concepts and model assumptions have real implications. In Table 1, we include the average absolute (additive)279
and log-transformed (multiplicative) change in pain scores for each dataset. As an example, the effect of280
naproxen relative to no treatment in Placebo II is -15 (-27,-3) for the additive model but 0.7 (0.4, 1.1) for281
the multiplicative model. The 95% CI is much wider for the multiplicative model since it is misspecified,282






Placebo I -3 (-12, 5) 0.9 (0.8, 1.1)
Placebo II Placebo: -9 (-21, 4)
Naproxen: -15 (-27, -3)
Placebo: 0.8 (0.5, 1.3)
Naproxen: 0.7 (0.4, 1.1)
Levodopa Trial 4 (-7, 15) 1.5 (0.7, 3.3)
Table 1: Additive and multiplicative effects by dataset. All effects were modeled using ANCOVA with
pre-intervention scores as a covariate. Multiplicative effects use the log-transformed scores and represent the
exponentiated coefficients which can be interpreted as the relative effect of treatment group versus the control
group (e.g., post-intervention pain in the placebo group (Placebo I) will be 90% of the post-intervention pain






Pain relief is a ubiquitous clinical trial outcome with direct treatment implications. Treatments that yield285
appreciable pain relief will be employed in the clinic, and findings from these trials may be communicated286
to patients. However, if data from trials are not properly modeled, then the resulting treatment effects287
may be both biased and highly variable, which in turn may mislead researchers, clinicians, and patients.288
In this theory-based paper, we have emphasized the difference between additive and multiplicative treating289
effects from mathematical, statistical, and empirical perspectives. It is clear that the assumptions behind290
these effects are not interchangeable and thus should be more thoughtfully considered when planning and291
analyzing clinical trial data. Moreover, how pain relief is conceptualized will propagate into the interpretation292
of effects, which we briefly discuss herein.293
4.1 Minimal Clinically Important Differences294
Pain intensity ratings can be difficult to interpret—they are a reductionist, unidimensional measurement in-295
tended to capture a single aspect of a private, complex, incommunicable experience [Chapman and Loeser, 1989,296
Turk and Melzack, 2011]. To help make sense of improvements, researchers and clinicians commonly rely297
on minimal clinically important differences (MCID). In clinical pain research, MCIDs are commonly de-298
rived by mapping changes in pain ratings onto a different scale, such as global impression of change299
[Farrar et al., 2001]. For example, what absolute change in NRS and relative change in NRS correspond300
to “much improved”? This mapping is then commonly used a guidepost for interpreting other studies, and301
in some cases, individual patient changes [Smith et al., 2020].302
Although commonly derived and used without justification, absolute and relative MCIDs are not inter-303
changeable since they are mathematically incompatible with one another. Suppose patient A starts with an304
8/10 pain and patient B starts with a 4/10 pain. If the treatment has an additive effect, both patients may305
improve by 2/10, but this would result in markedly different percent reductions: 25% and 50% for patients306
A and B, respectively. Farrar et al. [Farrar et al., 2001] suggest that an MCID for pain relief is 2/10 NRS or307
30%; here, these would yield two different conclusions since both patients achieved a 2/10 decrease but only308
one patient achieved a 30% decrease. Much attention has been and continues to be given to both additive309
and multiplicative MCIDs without considering the conceptual difference between the two. This conceptual310
incompatibility needs to be reconciled if MCIDs are to be used in a meaningful way. However, there are also311
larger issues that warrant addressing.312
Across studies and ignoring the numerical nature of treatment effects, MCIDs have a linear relationship313
with baseline pain ratings, with an x-intercept corresponding to roughly 30/100 and a slope of 1 (i.e.,314
MCID ≈ baseline− 30) [Olsen et al., 2018]. This relationship calls into question both absolute and relative315
MCIDs. If absolute MCIDs were valid, then we would expect the MCID to be constant across all baseline316
pain scores. If relative MCIDs were valid, then we would expect a y-intercept of 0 and a slope equal to the317
MCID. Rather, this relationship suggests MCIDs are more compatible with a post-intervention pain rather318
than change score, and this post-intervention pain is equal to 30/100. In other words, the MCID is the319
change in pain needed to obtain a 30/100. If true, this would be consistent with the idea that it is a patient’s320
pain, not change in pain, that is important.321
More generally, MCIDs arguably represent a conflation of constructs. MCIDs typically involve di-322
chotomizing a measurement by mapping it onto some other measurement using some loss function—a form323
of ‘dichotomania’ [Senn, 2005]. For example, researchers may threshold and dichotomize changes in VAS324
into improvement versus non-improvement using the global impression of change scale [Farrar et al., 2001].325
This dichotomization of pain scores is then applied to other studies. Yet, such an approach is curious—it326
implies we are actually interested in global impression of change but use pain scores as a noisy proxy. If327
a researcher is interested in global impression of change, they should measure global impression of change328
as an outcome in their sample. Further, the ontological basis for dichotomous change scores is arguably329
ill-conceived. The insipid use of MCIDs in pain research and practice deserves greater scrutiny. From this330
perspective, it has been argued that greater context is needed in deriving metrics of clinical importance331
[Ferreira et al., 2012, Ferreira, 2018] for which decision theory may provide a rigorous foundation.332
In addition to using MCIDs for interpreting findings, researchers have used MCIDs for ‘responder anal-333





on whether their change in pain exceed the MCID (see Section 4.5 in [Smith et al., 2020]). However, such335
analyses have undesirable properties on both the individual and group levels. On the individual level, in-336
ferences cannot be made regarding response magnitude for several reasons. First, individual counterfactuals337
are not observed in parallel group trials; for example, we do not know what what an individual’s pain would338
have been had they been randomized to the placebo group instead of the drug group. An individual’s339
observed improvement or worsening may have been due to the intervention or alternatively, RTM, natural340
history, or some other unmeasured, stochastic process. Second, the individual may not reliably attain the341
same improvement each time the trial is performed; for example, 60% of individuals may respond 100%342
of the time or 100% of individuals may respond 60% of the time (or some mixture of the two). Third,343
this dichotomization assumes an improvement of, say, 30% and 100% are equivalent, and similarly, that344
an improvement of 29% and 0% are equivalent (assuming MCID = 30%) by treating improvements as a345
binary step function rather than continuous—such an assumption strains credulity. These issues have been346
previously discussed in great detail [Senn, 2001, Senn, 2004, Senn, 2016, Senn, 2018]. On the group level,347
dichotomizing individual responses turns each patient’s pain improvement into a 0 (‘non-responder’) or 1348
(‘responder’), which discards information and, in turn, markedly decreases statistical efficiency and power349
[Cohen, 1983, Altman and Royston, 2006]. Thus, the dichotomization of improvements is arguably unethical350
since it discards information, effectively decreasing the sample size [Cohen, 1983] and, in turn, the ability351
to quantify (or rule out) meaningful intervention effects. Rather than being treated as an analytical tool,352
MCIDs are perhaps better viewed from an interpretive and decision-making perspective.353
Notwithstanding MCID’s limitations, it is perhaps most useful at the planning stage of clinical research.354
A clinically important difference is just one approach to justifying an effect size of interest for a study355
[Cook et al., 2018], which may be used for sample size calculations or stopping rules in adaptive trials.356
However, beyond planning, dichotomizing trial and especially individual patient outcomes using an MCID357
is a questionable practice that commonly ignores context and variability [Senn and Julious, 2009].358
4.2 Scale Assumptions359
Psychological measurement scales have a rich history across the fields of psychometrics and psychophysics360
[Stevens, 2017]. Anchors determine the extremes within which a participant must rate their experience,361
ultimately constraining the measurement construct and how accurately participants understand what they362
are rating [Yokobe et al., 2014]. Bounded by these anchors, the measurements themselves can be on one363
of a number of scales: nominal, ordinal, interval, ratio, and absolute. Nominal scales assume a one-364
to-one mapping between the desired quantity x′ and the measured quantity x; ordinal scales assume a365
monotonic mapping; interval scales assume an affine mapping (x′ = ax + b); ratio scales assume a lin-366
ear mapping with an absolute zero (x′ = ax); and absolute scales assume a perfect mapping (x′ = x)367
[Bolanowski Jr and Gescheider, 2013]. Several renowned psychophysicists have argued—not without criti-368
cism [Ellermeier and Faulhammer, 2000, Zimmer, 2005]—that perceptual ratings are or can easily be con-369
verted to ratio scale [Stevens, 2017, Bolanowski Jr and Gescheider, 2013]. Importantly, the additive and370
multiplicative models rely on interval and ratio assumptions, respectively. Thus, the validity of these as-371
sumptions for clinical pain must be considered.372
The numerical nature of clinical pain is an open, controversial, and perhaps unanswerable question. Early373
psychophysics work argues that VAS and NRS pain scales are ratio for both experimental and clinical pain. In374
1983, Price et al. [Price et al., 1983] used cross-modality matching to argue that clinical pain, like heat pain,375
is a ratio scale. However, by mapping clinical pain onto heat pain, this finding is arguably tautological—376
they assessed whether clinical pain-matched heat pain follows the same power law as heat pain. Others377
have used item-response theory to argue that pain ratings are ordinal scale (nonlinear) rather than ratio or378
interval scale [Kersten et al., 2014]. Since the authors used unidimensional measures and a Rasch model, this379
conclusion is based on stationarity assumptions and ratings’ reliability, which are not necessary conditions380
for interval or ratio scales. Although the perceptual ratings from psychophysics are undoubtedly related to381
clinical pain, assessing the measurement properties of clinical pain is much more complex since we cannot382
precisely control the sensory input. Thus, clinical pain measurement scale assumptions arguably cannot be383
rigorously evaluated, reinforcing that they are indeed assumptions. However, the strength of assumption384
varies, with interval scales (additive) having weaker assumptions than ratio scales (multiplicative). The385




4.3 Statistical Modeling and Applications387
The choice of a statistical model can greatly affect the inferences drawn from the same dataset. Here, we388
observed that applying a multiplicative model to a dataset that exhibits additive properties can create wide389
CIs, making it difficult to interpret the results of an experiment (Table 1). This is consistent with the390
idea that a properly specified model will be more statistically efficient [Vickers, 2014], and perhaps most391
importantly, they better represent the underlying data.392
We presented two ways of modeling data: additively and multiplicatively. Both rely on ANCOVA,393
with the former using raw pain scores and the latter using log-transformed pain scores. These models394
have different assumptions about the underlying data and, as a result, have different interpretations. If395
authors feel the linearity and ratio assumptions are too strict, there are other models that can be used;396
e.g., ordinal regression and semiparametric (or nonparametric) ANCOVA [Harrell, 2017], in addition to397
intensive longitudinal and time-series analysis [Fitzmaurice, 2011]. Indeed, there are good examples in398
the pain literature of ANCOVA-type models being implemented with more complicated data structures399
(e.g., multiple study endpoints, see [Mathieson et al., 2017]). In any case, researchers should be aware of400
the assumptions of their statistical models of the properties of their data, and of course, researchers are401
encouraged to collaborate with statisticians [Sainani et al., 2021].402
4.4 Recommendations403
We have clearly demonstrated the mathematical, conceptual, and interpretive differences between additive404
and multiplicative effects. From this explication, there are tangible takeaways and recommendations for405
clinical researchers. Specifically, we suggest that researchers include and consider the following:406
1. When deciding which metric to use—absolute pain decreases or percent pain decreases—use the data as407
a guide unless there is a principled reason to choose one or the other. Since it is unclear what influences408
the presence of additive or multiplicative characteristics in pain data, it is safer to use the metric that409
exhibits the properties of the data accurately. Table 2 summarizes the differences between additive410
and multiplicative properties. In time, we may develop a better understanding of pain conditions and411
improvements such that more general recommendations can be provided. We view this as being no412
different than checking statistical model assumptions.413
Table 2: Hallmarks of additive and multiplicative effects.
Plot Additive Multiplicative
Slope of change score vs.
pre-intervention score (y)
vs. number of points (x)
Slopes approach zero as the
number of points utilized in
calculating pre- and
post-intervention pain scores
increases by increasing ICC
(Figure 3, left).
Slopes increase minimally with
increasing number of points
(Figure 3, right).
Absolute value of residuals
(y) vs. fitted values (x)
No relationship between




residual error and fitted
(post-intervention) values.
2. When reporting descriptive statistics, use the arithmetic mean to calculate between-subject (average)414
intervention for additive data; conversely, use geometric mean for multiplicative data.415
3. Ensure that patients’ pre-intervention scores are heterogeneous for drawing conclusions about the416
nature of the data. By including a wide range of pre-intervention scores, it makes the additive or417
multiplicative properties more apparent. If the data are not heterogeneous, false conclusions may be418





The properties of changes in self-reported pain are commonly implicitly assumed to be additive, multiplica-421
tive, or are conflated. Ignoring the properties of pain relief can result in model misspecification, in turn422
leading to bias and statistical inefficiency. These errors further propagate into metrics such as minimal423
clinically important differences. We contend that more attention should be paid to the statistical properties424
of pain relief to ensure model assumptions are met. By paying closer attention to these properties, we can425
gain more insight from and make better use of data from pain clinical trials.426
A Data Generating Processes427
A.1 Additive Model428
The additive model can be conceptualized hierarchically. First, we will assume each individual’s average429






Since αi represents an individuals average pre-intervention pain, it is a latent construct and ignores mea-431
surement error and natural pain variability; for example, minute-to-minute, hour-to-hour, and day-to-day432
fluctuations in pain intensity. In actuality, an experiment will sample an individual’s pain ratings and will433
be affected by measurement error. Thus, a given measurement of a patient’s pre-intervention pain will be434
xij = αi + εij ,




for measurement j from patient i, assuming all patients have the same within-patient435








Similarly, assuming homogeneous improvement and treatment effects, the average post-intervention pain437
rating for patient i is438
yi· ∼ N
#





where δ is the improvement in the control group, θ the treatment effect of interest, and gi is a dummy439
variable for group (0 = control; 1 = intervention). Without loss of generality via the additive assumption of440
treatment effects, we will ignore treatment groups (θ) to simplify the problem and describe the properties of441















which is also the correlation between pre- and post-intervention scores. Luckily, ICC is sensitive to the444












With more data points, the slope attributable to RTM disappears. Since the ICC is equivalent to a Pearson’s446


























The log-normal distribution is an exponentiated normal distribution, meaning the log of the log-normal450















And like the additive case, a single pre-intervention score j pain for patient i can be described as being452
centered around their individual mean,453







Similarly, a patient’s post-intervention pain is scaled rather than shifted by the change in pain, δ,454
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